Exploring glycosylated RNAs as new targets for aggressive prostate cancer.
Developing glycosylated RNAs as novel clinical targets for aggressive prostate cancer.
This study is looking at special changes in RNA that might affect how prostate cancer grows and how well patients do, with the goal of finding better ways to treat advanced prostate cancer and help doctors make more personalized treatment plans for men facing this disease.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Old Dominion University NIH-funded |
| Lab location | 1 site (Norfolk, United States) |
| Project ID | NIH-11097595 on NIH RePORTER |
What this research studies
This research aims to investigate glycosylated RNAs in the context of prostate cancer, which is a leading cause of cancer-related deaths among men. The study will explore how these RNA modifications can influence tumor behavior and patient outcomes. By understanding the role of glycosylated RNAs, researchers hope to improve patient stratification and develop new therapeutic options for advanced prostate cancer. This work involves advanced biochemical techniques to analyze RNA modifications in cancer cells.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with prostate cancer, particularly those with high-grade or metastatic disease.
Not a fit: Patients with early-stage prostate cancer or those who do not have prostate cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that significantly improve survival rates for patients with aggressive prostate cancer.
How similar studies have performed: While the exploration of glycosylated RNAs in cancer is a relatively novel approach, similar studies have shown promise in understanding RNA modifications in other cancer types.
Where this research is happening
Norfolk, United States
- Old Dominion University — Norfolk, United States (Active)
Researchers
- Principal investigator: Kerscher, Aurora Esquela — Old Dominion University
- Study coordinator: Kerscher, Aurora Esquela
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.